Download
analysis databases a regulatory perspective n.
Skip this Video
Loading SlideShow in 5 Seconds..
Analysis Databases: A Regulatory Perspective PowerPoint Presentation
Download Presentation
Analysis Databases: A Regulatory Perspective

Analysis Databases: A Regulatory Perspective

258 Vues Download Presentation
Télécharger la présentation

Analysis Databases: A Regulatory Perspective

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Analysis Databases:A Regulatory Perspective Steve Wilson, DrPH Deputy Director Division of Biometrics II/FDA/CDER 2003 FDA/Industry Statistics Workshop "Statistics: From Theory to Regulatory Acceptance“ Parallel Session II: Analysis Databases Hyatt Regency, Bethesda, Maryland September 18-19, 2003

  2. Analysis Databases:Let’s Get a Guidance Pronto Steve Wilson, DrPH Deputy Director Division of Biometrics II/FDA/CDER 2003 FDA/Industry Statistics Workshop "Statistics: From Theory to Regulatory Acceptance“ Parallel Session II: Analysis Databases Hyatt Regency, Bethesda, Maryland September 18-19, 2003

  3. Disclaimer Views expressed in this presentation are those of the speaker and not, necessarily, of the Food and Drug Administration

  4. Outline • The way we were • The way we are • Standards development • The urgent need for a guidance on the submission of analysis files • New eCTD guidance • Developing a guidance • CDISC and ADaM

  5. The Way We Were • Statistical review focused on efficacy • Data submitted to reviewers (“desk copies”) • No EDR • No archive standards (e.g., Transport 5, PDF, …) • The luxury of time (pre-PDUFA) • Less workload • Delayed decisions • Encourage, but not insist • Every study a new challenge • Routine analyses • Pharmaceutical development separate from healthcare.

  6. The Way We Are • Risk-Benefit / Safety - Efficacy • Medical reviewers “want” data for “analysis” • PDUFA limits time and options • Tough realities related to Science (no more knee-jerk LOCF) • Approvable cycles • Submission standards (Transport 5, PDF) • Reviewer templates • Data “warehouse” – more standards (HL7, Version 3, SDS, CDISC, HIPAA, etc.)

  7. Standards Development : A Sea of Terms & Acronyms CDISC SDM Version 3 RCRIM AERS HL7 ODM ADaM WEBSDM MeDRA eCTD JANUS PPV ICH SNOMED HIPaa 911 XML 21 CFR 11

  8. Standards Development • ICH E3 – study description • eCTD – electronic Common Technical Document (submission guidance, Booze-Allen viewer tools) • Submission Data Standards (CDISC Version 3, PPV Pilot, Lincoln Tech CRADAs –PPV and WEBSDM HL7/RCRIM, JANUS) • Protocols • ICH E6, E9 and E3 • Statistical analysis plan • Consistency – impossible task?

  9. I Contend That … • It is important that we (statisticians, the industry, clinical trialists, regulators, researchers) need to agree on and use standards for describing an analysis database and analyses -- for a study and for combined studies. • This is true for Science and regulation • We need a guidance. • We need to use the guidance to document and communicate the scientific decisions we make in analyzing data

  10. eCTD Draft Guidance: August 2003 Guidance for Industry Providing Regulatory Submissions in Electronic Format — Human Pharmaceutical Product Applications and Related Submissions DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit comments to Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the Federal Register. For questions regarding this draft document contact (CDER) Randy Levin 301-594-5411, or (CBER) Robert Yetter at 301-827-0373.

  11. eCTD Draft Guidance: Finding a “Home” for Analysis Files 1. Study reports Typically, a single document should be provided for each study report included in this module. However, if you provide the study reports as multiple documents, you should confine the subject matter of each document to a single item in the following list… Individual subject data listings … -- Analysis datasets - Analysis datasets - Analysis programs - Data definitions [my emphasis]

  12. Developing Guidance for Analysis Databases: Some Challenges • Keeping Science alive – complexity (The Battle of the Comments) • Improving the Science (data quality; missing data – “gets hard real fast” – O’Neill, 2003 FDA/ASA Biopharm Workshop; safety and efficacy • Efficient, unambiguous communication (recent experience) • Everybody already knows what to do • Include health research enterprise and new technologies

  13. Regulation Guidance Regulatory Environment S. Woollen

  14. Guidance Begets Guidance:Be Careful of the Consequences • Providing Regulatory Submissions in Electronic Format — NDAs • Provided advice on submitting “CRT” (case report tabulation) data • Details on safety data and demographics • “lists contain suggested data elements for the individual datasets. This listing is meant to serve as a starting point for discussion between you and the review division on the content and organization of the datasets” • Our advice led to confusion

  15. Developing Guidance • Best advice – reflect best practice • Pay attention to current practice & Science (meetings with sponsors) • Talk to “customers” – series of meetings • Ask experts – Dave Christiansen, SGE • Coordinate with other guidances – HL7 • We need to do it – eStat Group • Provide draft for comments • Not regulation – comment: very fuzzy • New urgency – guidance on submission of analysis files

  16. Did Get People Together for the First Time to Talk Standard: CDISC • Workgroups • SDM (submission data) • ODM (operational data – XML • ADaM (analysis data) • Lab (laboratory data) • Challenge – coordinate efforts • ADaM – doing the hard work • We (FDA) are “observers”

  17. ADaM focus – FDA Statisticians • “provide guidelines for the creation of files and associated documentation that are submitted to the FDA statistical reviewer in support of the primary and important secondary study objectives” • “statistical analysis data models represent consensus across a large number of reviewers experienced in regulatory review” • A big jump start for us – re. guidance

  18. ADaM Models: One PROC Away • “Statistical Analysis Dataset Models” • Change-from-baseline • Time-to-event • Categorical • Safety (under construction) • Detailed examples • Detailed description of data files and corresponding metadata (SDM) • Example based on real endpoint • Display tables • Test data

  19. ADaM Models: The Power of Standards

  20. Are We There Yet?More Guidance • Statistical Analysis Plans • E3 – Appendix 16.1.9 Documentation of statistical methods • Protocols

  21. THANK YOUSee You Next Year! wilsons@cder.fda.gov 301-827-5583